
Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center
Advertisement
Articles by Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center
Advertisement
Latest Updated Articles
Management of Adverse Effects in R/R HER2+ mBCSeptember 23rd 2020
FDA-approved Therapies for Relapsed/Refractory HER2+ mBCSeptember 23rd 2020
Practical Management of Early Stage HER2+ Breast CancerSeptember 23rd 2020
HER2-targeted Therapy: Routes of AdministrationSeptember 23rd 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC
4
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
5



